miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase

被引:197
作者
Zhou, Yunfei [1 ]
Wan, Guohui [1 ]
Spizzo, Riccardo [2 ]
Ivan, Cristina [2 ]
Mathur, Rohit [1 ]
Hu, Xiaoxiao [1 ]
Ye, Xiangcang [3 ]
Lu, Jia [1 ]
Fan, Fan [3 ]
Xia, Ling [3 ]
Calin, George A. [2 ]
Ellis, Lee M. [3 ]
Lu, Xiongbin [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
Chemoresistance; miR-203; ATM; DNA damage response; Oxaliplatin; MICRORNA EXPRESSION; MESENCHYMAL TRANSITION; FLUOROURACIL; LEUCOVORIN; GROWTH; SENSITIVITY; INDUCTION; PROGNOSIS; THERAPY; TUMORS;
D O I
10.1016/j.molonc.2013.09.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Chemotherapy for patients with metastatic colorectal cancer (CRC) is the standard of care, but ultimately nearly all patients develop drug resistance. Understanding the mechanisms that lead to resistance to individual chemotherapeutic agents may help identify novel targets and drugs that will, in turn, improve therapy. Oxaliplatin is a common component combination therapeutic regimen for use in patients with metastatic CRC, but is also used as a component of adjuvant therapy for patients at risk for recurrent disease. In this study, unbiased microRNA array screening revealed that the miR-203 microRNA is up-regulated in three of three oxaliplatin-resistant CRC cell lines, and therefore we investigated the role of miR-203 in chemoresistance. Exogenous expression of miR-203 in chemo-naive CRC cells induced oxaliplatin resistance. Knockdown of miR-203 sensitized chemoresistant CRC cells to oxaliplatin. In silico analysis identified ataxia telangiectasia mutated (ATM), a primary mediator of the DNA damage response, as a potential target of miR-203. ATM mRNA and protein levels were significantly down-regulated in CRC cells with acquired resistance to oxaliplatin. Using TCGA database, we identified a significant reverse correlation of miR-203 and ATM expression in CRC tissues. We validated ATM as a bona fide target of miR-203 in CRC cells. Mutation of the putative miR-203 binding site in the 3' untranslated region (3'UTR) of the ATM mRNA abolished the inhibitory effect of miR-203 on ATM. Furthermore, stable knockdown of ATM induced resistance to oxaliplatin in chemo-naive CRC cells. This is the first report of oxaliplatin resistance in CRC cells induced by miR-203-mediated suppression of ATM. (C) 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:83 / 92
页数:10
相关论文
共 51 条
[1]
Platinum-DNA Interactions and Subsequent Cellular Processes Controlling Sensitivity to Anticancer Platinum Complexes [J].
Ahmad, Saeed .
CHEMISTRY & BIODIVERSITY, 2010, 7 (03) :543-566
[2]
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group Phase II study [J].
Alberts, SR ;
Horvath, WL ;
Stcrnfeld, WC ;
Goldberg, RM ;
Mahoney, MR ;
Dakhil, SR ;
Levitt, R ;
Rowland, K ;
Nair, S ;
Sargent, DJ ;
Donohue, JH .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9243-9249
[3]
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[4]
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis [J].
Bartkova, J ;
Horejsi, Z ;
Koed, K ;
Krämer, A ;
Tort, F ;
Zieger, K ;
Guldberg, P ;
Sehested, M ;
Nesland, JM ;
Lukas, C ;
Orntoft, T ;
Lukas, J ;
Bartek, J .
NATURE, 2005, 434 (7035) :864-870
[5]
MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma [J].
Boll, K. ;
Reiche, K. ;
Kasack, K. ;
Moerbt, N. ;
Kretzschmar, A. K. ;
Tomm, J. M. ;
Verhaegh, G. ;
Schalken, J. ;
von Bergen, M. ;
Horn, F. ;
Hackermueller, J. .
ONCOGENE, 2013, 32 (03) :277-285
[6]
Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells [J].
Bose, D. ;
Zimmerman, L. J. ;
Pierobon, M. ;
Petricoin, E. ;
Tozzi, F. ;
Parikh, A. ;
Fan, F. ;
Dallas, N. ;
Xia, L. ;
Gaur, P. ;
Samuel, S. ;
Liebler, D. C. ;
Ellis, L. M. .
BRITISH JOURNAL OF CANCER, 2011, 105 (11) :1759-1767
[7]
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers [J].
Calin, GA ;
Sevignani, C ;
Dan Dumitru, C ;
Hyslop, T ;
Noch, E ;
Yendamuri, S ;
Shimizu, M ;
Rattan, S ;
Bullrich, F ;
Negrini, M ;
Croce, CM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (09) :2999-3004
[8]
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer [J].
Cassidy, Jim ;
Clarke, Stephen ;
Diaz-Rubio, Eduardo ;
Scheithauer, Werner ;
Figer, Arie ;
Wong, Ralph ;
Koski, Sheryl ;
Lichinitser, Mikhail ;
Yang, Tsai-Shen ;
Rivera, Fernando ;
Couture, Felix ;
Sirzen, Florin ;
Saltz, Leonard .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) :2006-2012
[9]
interview [J].
Chen, Lawrence .
ELECTRONICS LETTERS, 2013, 49 (01) :4-4
[10]
Dai Z, 2004, CURR TOP MED CHEM, V4, P1347